CareDx (CDNA) vs NeoGenomics (NEO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CareDx (CDNA) has outperformed NeoGenomics (NEO) over the past year, gaining 329.7% versus a gain of 76.9%. Over five years, CDNA leads with a -11.2% price change compared with -63.2% for NEO. CareDx is the larger company by market cap ($3.26 billion vs $2.05 billion), about 1.6 times the size.
On valuation, NeoGenomics trades at a lower forward P/E (47.1x vs 48.9x for CareDx).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDNA | NEO |
|---|---|---|
| Share price | $63.04 | $15.97 |
| Market cap | $3.26B | $2.05B |
| 1-day change | -1.18% | -3.24% |
| YTD return | +234.61% | +35.80% |
| 1-year return | +329.72% | +76.85% |
| 5-year return | -11.21% | -63.19% |
| P/E ratio (TTM) | 30.31 | — |
| Forward P/E | 48.87 | 47.10 |
| EPS (TTM) | $2.08 | $-0.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $72.51 | $20.15 |
| 52-week low | $13.95 | $7.07 |
| Distance from 52-week high | -13.06% | -20.74% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -6.68% | +34.94% |
| Average volume | 1.28M | 2.36M |
| Shares outstanding | 51.73M | 128.48M |
| Employees | 761 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Precision Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CDNA has outperformed NEO by 252.9 percentage points over the past year.
About CareDx
CDNA stock →CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
Health Care · Medical Specialities · 761 employees
About NeoGenomics
NEO stock →NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom.
Health Care · Precision Instruments · 2,500 employees
CDNA vs NEO FAQ
Which is bigger, CareDx or NeoGenomics?
CareDx (CDNA) is larger, with a market capitalization of $3.26B compared with $2.05B for NeoGenomics (NEO).
Which stock has performed better over the past year, CDNA or NEO?
CDNA returned +329.72% over the past 12 months, compared with +76.85% for NEO (price return, excluding dividends). Past performance does not predict future results.
Are CareDx and NeoGenomics in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for CareDx and Precision Instruments for NeoGenomics.